- MyIllumina
- Tools
At Illumina, we work collaboratively with you to achieve your research objectives. Since 2002, we have consistently provided on-time, reliable genotyping services to academic and pharmaceutical customers, through our in-house expert molecular geneticists using Illumina's cutting-edge SNP genotyping technologies. Enjoy the same competitive advantage that our installed base customers have to conduct whole-genome association studies, linkage analysis, and fine mapping studies in a timely fashion at a reasonable cost. Take advantage of Illumina's full menu of FastTrack Genotyping Services and enjoy the following key benefits:
- Personalized service with dedicated and collaborative experts
- Reliable, proven, and speedy process
- Industry-leading data quality
- Comprehensive study types
For more information on Illumina's industry-leading genotyping products, see the Infinium Whole-Genome Genotyping and GoldenGate Genotyping product selector.
|
Infinium Whole-Genome genotyping Past Performance* (Based on all contracts between 2006 and 2008, > 60,000 BeadChips and 36 billion genotypes):
|
|||||||
|---|---|---|---|---|---|---|---|
| Infinium Service Projects | Average | ||||||
| Locus Success Rate | 91.9% | ||||||
| DNA Success Rate | |||||||
| - Genomic DNA - Whole-genome amplified DNA |
98.2% 98.8% |
||||||
| Call Rate | 99.8% | ||||||
| Reproducibility | > 99.99% | ||||||
| Trio Inconsistency | 99.91% | ||||||
|
|
|||||||
|
GoldenGate Past Performance*
(Based on all contracts between 2006 and 2008, > 120,000 DNA samples from 75 projects): |
|||||||
|---|---|---|---|---|---|---|---|
| GoldenGate Service Projects | Average | ||||||
| Custom Assay Locus Success - Human only - Non-human Species |
94.3% 83.8% |
||||||
| DNS Requiements -Genomic DNA -Whole-genome amplified DNA |
98.3% 79.6% |
||||||
| Call Rate | 99.3% | ||||||
| Reproducibility | > 99.99% | ||||||
| Trio Inconsistency | 99.89% | ||||||
|
|
|||||||
Additional Information
At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina's innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.